CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Conjugated estrogens/norgestrel

Progestogens and estrogens, fixed combinations

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 4, 2026
Entity authorityQ84768876 ↗
Source-derived summary

Conjugated estrogens/norgestrel (CEEs/NG), sold under the brand name Prempak-C among others, is a combination of conjugated estrogens (CEEs), an estrogen, and norgestrel (NG), a progestin, which is used in menopausal hormone therapy in postmenopausal women. It is taken by mouth and contains 0.625 or 1.25 mg CEEs and 150 μg NG (or 75 μg levonorgestrel) per tablet. The medication is no longer marketed.

Editorial summary

This brief starts where responsible research should: with the source description of “Conjugated estrogens/norgestrel” as progestogens and estrogens, fixed combinations. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA dependable orientation record for establishing vocabulary, names and a first evidence trail. The current 63-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. The account is most persuasive where Conjugated, estrogens and norgestrel can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the general reference register because the source frames it as progestogens and estrogens, fixed combinations. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 4, 2026. The linked authority identifier is Q84768876. None of the 0 selected statements returned an explicit reference.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Conjugated estrogens/norgestrel”, its source revision and the description used here.
  2. Expand the search: follow Conjugated estrogens/norgestrel primary sources, Conjugated estrogens/norgestrel archive and Conjugated research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Conjugated estrogens/norgestrel”?
  2. Which institution is responsible for the underlying evidence?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Conjugated estrogens/norgestrel” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.